Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vesicare With or Without Behavioral Modification for Overactive Bladder
NCT00821184Phase 3Terminated
- Sponsor
- Lahey Hospital & Medical Center
- Start
- Sep 2006
- Primary completion
- Sep 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised trial of solifenacin in overactive bladder (OAB) (2 arms), sponsored by Lahey Hospital & Medical Center. Primary endpoint: Change From Baseline in the Number of Incontinence Episodes Per 24 Hours at 12 weeks. Started Sep 2006; status: terminated.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00821184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00821184.